GlassScriptPhysician profile
John P Abad
NPI 1356376800
$15,224.39
in general payments reported to CMS, 2019-2025
63 companies · $2,491 in 2025
The $2,491 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,109 · 2020: $1,190 · 2021: $2,136 · 2022: $2,411 · 2023: $2,594 · 2024: $2,293 · 2025: $2,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,378.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,158.83 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,525.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,475.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,397.72 | 2019-2025 | |
| Lilly USA, LLC | $1,281.01 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,165.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.87 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $608.00 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $394.80 | 2019-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $388.33 | 2021-2025 | |
| Abbott Laboratories | $338.74 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $337.39 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $296.40 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.47 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Sanofi-Aventis U.S. LLC | $245.52 | 2019-2025 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.